Take an in-depth look at San Diego's vibrant life sciences sector with our annual publication, Inside Biotech.

  • Local researchers create business as well as DNA in emerging field

    To tackle some of the world’s most difficult problems, scientists are turning to a very complex form of research called synthetic biology.

  • Pfizer arthritis drug quenched pain too well, leading to damage

    An experimental arthritis drug from Pfizer Inc. reduced pain more than researchers anticipated, doctors said. It also allowed previously hobbled patients to overuse and permanently damage their joints.

  • Attorneys see encouraging news in appellate court reversal of embryonic stem cell ban

    The biotech world in San Diego -- and around the country -- anxiously awaits the outcome of a court case involving government funding of embryonic stem cell research.

  • Obscenity, whale snot take top honors at Ig Nobels

    BOSTON -- Next time you crush your thumb with a hammer and you're in extreme pain, go ahead, let fly with every filthy obscenity you know.

  • Feds: Novartis to pay more than $400 million in penalties

    PHILADELPHIA -- Novartis Pharmaceuticals Corp. will plead guilty to charges it marketed an epilepsy medicine for unapproved uses and pay $422.5 million in civil and criminal penalties, federal officials announced Thursday.

  • Harvard method turns skin to stem cell alternative with less cancer risk

    A novel way to create stem cells from skin reduces the risk of cancer caused by the original method and may open the way to treatments for genetic diseases.

  • Amgen drug may block some breast cancer, studies hint

    Amgen Inc.’s (Nasdaq: AMGN) denosumab, approved to treat osteoporosis and being tested to reduce the spread of cancer to bones, may have potential to treat a type of breast tumor, early research suggests.

  • Recalled drugs tied to heart risk spurs call for FDA review

    Half of the 21 drugs pulled from the market in the U.S. for safety reasons since 1995 involved heart complications, a finding that is spurring Congress and doctors to call for closer government review of side effects.

  • Stem cells test drugs in a dish, may speed tests and save millions in cost

    Six months ago, Roche Holding AG scientists disrupted the rhythmic beating of heart muscle made from stem cells by adding a cancer drug to it, duplicating in the laboratory a side effect previously only seen in patients.

  • Drugs before surgery help women avoid mastectomies

    Taking hormone-blocking pills for a few months before breast cancer surgery can shrink tumors and allow many women to have just the lump removed instead of the whole breast, a new study suggests.

  • FDA delays decision on breast cancer drug Avastin

    WASHINGTON -- Drugmaker Roche said last Friday that U.S. health regulators will take more time to review its drug Avastin for breast cancer, a use that has generated vigorous debate among cancer specialists and patients.

  • How to widen the hunt for targeted cancer therapy

    WASHINGTON -- Cancer is a tale of two sets of genetic code, your own and your tumor's -- and tracing the unique areas of damage makes for a way to target treatment.

  • Genetically altered salmon? It doesn't stop there

    WASHINGTON -- We've always played with our food -- even before we knew about genes or how to change them.

  • Murrieta expands its biotechnology business cluster

    A major focus of the City of Murrieta Economic Development Strategy is to encourage the establishment of additional biosciences and other technology businesses in Murrieta and in the Southern California “Twin Cities” area, which consists of the neighboring cities of Murrieta and Temecula.

  • Fish & Richardson’s growing San Diego bio-pharma team

    During The Daily Transcript’s recent biotech roundtable, the participants shared an optimistic view of the future of the local biotechnology and pharmaceutical industries. Law firm Fish & Richardson shares this optimism and has expanded its San Diego team to accommodate the growing demand for experienced biotech and pharmaceutical attorneys.

  • Cushman & Wakfield has only local real estate team dedicated to biopharmaceutical industry

    The Cushman & Wakefield Life Sciences Group is San Diego County’s most experienced real estate team specializing exclusively in meeting the unique needs of the biotechnology industry. The group regularly negotiates more than 65 percent of all local life sciences transactions, totaling more than $1 billion and 5 million square feet of space -- making it the leading laboratory tenant rep group in the region.

  • Cassidy Turley helps clients find the right laboratory space

    The Cassidy Turley BRE Commercial Life Science Team understands the unique facility needs of today’s life science and pharmaceutical companies. We have extensive experience in the development, leasing and sales of laboratory facilities throughout the United States in the pharmaceutical, biopharmaceutical, biotechnology and medical device sectors. We offer expert guidance to assist you with all of your real estate requirements in the R&D, manufacturing, distribution and office asset classes.

  • Biotech space abounds – how to leverage the best lease

    The current market conditions are optimal for biotech companies -- or any type of tech operation -- to get a great deal on office, R&D or lab space. Whether you are coming toward the end of an existing lease term and considering renewal or you’re out on the market looking for new or expansion space, it’s always a good idea to understand the needs and motivations of potential landlords. Today, landlords need to eliminate vacancies and drive up their overall capitalized lease assets. As a result, potential tenants currently have significant opportunities to drive major concessions in exchange for signing a multiyear lease.

  • Santaris in Phase 2 clinical trials for Hepatitis C treatment

    Denmark-based Santaris Pharma, which has U.S.-based operations in San Diego, just announced it has received the green signal from the U.S. Food & Drug Administration to conduct phase two trials for miravirsen, a micro ribonucleic acid-targeted drug intended for the treatment of Hepatitis C virus, a liver disease.

  • Biopharmaceutical company to search ocean depths for drug treatments

    Trius Therapeutics is trying to find treatments for infections that other drugs can’t stop, and the company is going to great lengths in its search.

  • Local life science market stabilizing as biotech REITS make acquisition run

    The San Diego County life science market is characterized by guarded optimism, as gradually improving business activity and more available financing set the stage for improved tenant activity later this year and in 2011, according to the Cushman & Wakefield Life Sciences Group.

  • Quidel’s diagnostic test receives FDA approval

    Quidel Corp. (Nasdaq: QDEL) said it has received clearance from the U.S. Food and Drug Administration for the sale of its QuickVue RSV 10 test for acute respiratory syncytial virus (RSV) infections.

  • MediciNova receives go-ahead for meth-addiction drug

    MediciNova Inc. (Nasdaq: MNOV) said it has received approval from the U.S. Food and Drug Administration to proceed with an initial trial of the company’s neurological drug candidate, ibudilast, as a potential therapy for methamphetamine addiction.

  • Cylene begins clinical trial, closes financing

    Cylene Pharmaceuticals Inc. said it will begin a phase one clinical trial of its cancer drug with $12 million from a financing that closed Friday.

Roundtables

Profiles

Biotech Roundtable Video

Interview with Raj Krishnan

Sept. 23, 2010 -- Executive Editor George Chamberlin speaks with Raj Krishnan, CEO of Biological Dynamics, about biotech issues like outsourcing and manufacturing.

National News

Archived Reports

Inside Biotech - 2009

This special, six-week long feature explores San Diego's lifestyle trends, including health, travel, dining, resorts, attractions, finance and more.